48
Participants
Start Date
March 25, 2014
Primary Completion Date
February 12, 2021
Study Completion Date
December 28, 2023
PF-04449913
PF-04449913 administered orally and continuously in 28 day cycles.
PF-04449913
PF-04449913 administered orally and continuously in 28 day cycles.
Low dose ARA-C (LDAC)
Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
PF-04449913
PF-04449913 administered orally and continuously in 28 day cycles.
Daunorubicin
Daunorubicin given using 60 mg/m2 for 3-days.
Cytarabine
Cytarabine 100 mg/m2 on days 1 through 7.
PF-04449913
PF-04449913 administered orally and continuously in 28 day cycles.
Azacitidine
Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
PF-04449913
PF-04449913 administered orally and continuously in 28 day cycles.
LDAC
Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Japanese Red Cross Nagoya First Hospital, Nagoya
Kobe University Hospital, Kobe
Tohoku University Hospital, Sendai
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Bunkyo-ku
National Cancer Center Hospital, Chuo-ku
Yamagata University Hospital, Yamagata
Akita University Hospital, Akita
Kyushu University Hospital, Fukuoka
Tokyo Medical University Hospital, Tokyo
Lead Sponsor
Pfizer
INDUSTRY